Get the Stockscreener App
0.4303
4.42%
-0.0199
Gelteq Ltd stock is traded at $0.4303, with a volume of 9,426.
It is down -4.42% in the last 24 hours and down -30.10% over the past month.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
See More
Previous Close:
$0.4502
Open:
$0.4461
24h Volume:
9,426
Relative Volume:
0.13
Market Cap:
$4.61M
Revenue:
$105.10K
Net Income/Loss:
$-4.30M
P/E Ratio:
-1.1658
EPS:
-0.3691
Net Cash Flow:
$-3.91M
1W Performance:
-21.59%
1M Performance:
-30.10%
6M Performance:
-38.53%
1Y Performance:
-66.38%
1-Day Range:
$0.43
$0.4495
1-Week Range:
$0.45
$0.5595
52-Week Range:
$0.387
$2.01
Gelteq Ltd Stock (GELS) Company Profile
Compare GELS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GELS
Gelteq Ltd
|
0.4303 | 4.61M | 105.10K | -4.30M | -3.91M | -0.3691 |
TAK
Takeda Pharmaceutical Co Adr
|
19.64 | 62.75B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.26 | 48.12B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.965 | 43.82B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.72 | 32.53B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.81 | 23.54B | 3.17B | 1.29B | 1.01B | 27.09 |
Gelteq Ltd Stock (GELS) Latest News
Gelteq Limited Ordinary Shares (NASDAQ: GELS) Share Price, GELS Stock News, GELS Share Price & Updates - kalkine.ca
Gelteq Limited Ordinary Shares (NASDAQ: GELS) Share Price, GELS Stock News, GELS Share Price & Updates - kalkine.com.au
GELS: Gelteq Ltd. Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher - benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Gelteq Ltd (GELS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Gelteq Ltd (GELS) Earnings Date & Reports & Earnings News - TradingKey
Gelteq Ltd (GELS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gelteq Ltd (GELS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GELS|Gelteq Ltd|Price:0.670|Chg%:-0.031 - TradingKey
Gelteq Ltd (GELS) Balance Sheet - TradingKey
Gelteq Ltd (GELS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gelteq Ltd (GELS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gelteq Ltd (GELS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gelteq Ltd (GELS) Cash Flow - TradingKey
Gelteq Ltd (GELS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gelteq Ltd (GELS) Institutional Confidence - TradingKey
Gelteq Ltd (GELS) Income Statement - TradingKey
GELS|Gelteq Ltd|Price:0.701|Chg%:-0.042 - TradingKey
Gelteq Limited (GELS) Surges 9.39%, Approaching Key Resistance at $0.78Value ETF - dars.gov.et
Gelteq | 3: Initial statement of beneficial ownership of securities- Givoni Nathan J - Moomoo
Gelteq | 3: Initial statement of beneficial ownership of securities- Karp Bradley Glenn - Moomoo
Gelteq (GELS) wins shareholder approval and closes $2.5M second tranche note - Stock Titan
GELSGelteq Ltd Short Interest - Finviz
GELSGelteq Ltd Latest SEC Filings - Finviz
Gelteq (GELS) faces $5.3M working capital deficit and rising debt - Stock Titan
Gelteq Company Profile & Introduction - Moomoo
Gelteq Ltd (GELS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gelteq Ltd (GELS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gelteq Ltd (GELS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gelteq Ltd (GELS) Institutional Confidence - TradingKey
Gelteq Ltd (GELS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gelteq Ltd (GELS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gelteq advances clinical programs across pharmaceutical and veterinary applications By Investing.com - Investing.com India
Gelteq advances clinical programs across pharmaceutical and veterinary applications By Investing.com - Investing.com Australia
Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs - The Manila Times
Gelteq lines up first human trial, vet study and $3.5M financing - Stock Titan
Gelteq Ltd (GELS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gelteq advances clinical programs across pharmaceutical and veterinary applications - Investing.com
Gelteq Ltd (GELS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gelteq Ltd (GELS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GELS Stock Rockets On Massive Volume As Traders Pile In - StocksToTrade
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
$Gelteq (GELS.US)$ thank you - Moomoo
GELSGelteq Ltd Earnings - Finviz
What's Going On With Gelteq Stock Friday?Gelteq (NASDAQ:GELS) - Benzinga
Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications - The Manila Times
Dogs accept gels that hide bitter medicine, Gelteq trials show - Stock Titan
Gelteq Ltd Stock (GELS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):